Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT04190550
Title Testing the Addition of an Anti-cancer Drug, Navtemadlin, to the Usual Treatments (Cytarabine and Idarubicin) in Patients With Acute Myeloid Leukemia
Recruitment Suspended
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors National Cancer Institute (NCI)
Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST